 | • レポートコード：QYR2104Z3510 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、リソソーム蓄積症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（酵素補充療法、幹細胞治療、基質減少療法、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・リソソーム蓄積症治療の市場動向 ・企業の競争状況、市場シェア ・リソソーム蓄積症治療の種類別市場規模（酵素補充療法、幹細胞治療、基質減少療法、その他） ・リソソーム蓄積症治療の用途別市場規模（病院、クリニック、その他） ・リソソーム蓄積症治療の北米市場規模2016-2027（アメリカ、カナダ） ・リソソーム蓄積症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・リソソーム蓄積症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・リソソーム蓄積症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・リソソーム蓄積症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Takeda、Pfizer、Sanofi、BioMarin Pharmaceutical、Actelion Ltd、Raptor Pharmaceutical、Protalix Biotherapeutics、Amicus Therapeutics） ・結論 |
Lysosomal storage disorders is a group of genetic metabolic diseases caused by enzyme deficiencies in various body cells.
The Gaucher’s Diseases indication segment is expected to be the most dominant segment in global lysosomal storage diseases therapeutics market.
Market Analysis and Insights: Global Lysosomal Storage Diseases Therapeutics Market
The global Lysosomal Storage Diseases Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Lysosomal Storage Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Lysosomal Storage Diseases Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Lysosomal Storage Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Lysosomal Storage Diseases Therapeutics market.
Global Lysosomal Storage Diseases Therapeutics Scope and Market Size
Lysosomal Storage Diseases Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Lysosomal Storage Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Other
Segment by Application
Hospitals
Clinics
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Takeda
Pfizer
Sanofi
BioMarin Pharmaceutical
Actelion Ltd
Raptor Pharmaceutical
Protalix Biotherapeutics
Amicus Therapeutics
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lysosomal Storage Diseases Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Enzyme Replacement Therapy
1.2.3 Stem Cell Therapy
1.2.4 Substrate Reduction Therapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Lysosomal Storage Diseases Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Lysosomal Storage Diseases Therapeutics Market Perspective (2016-2027)
2.2 Lysosomal Storage Diseases Therapeutics Growth Trends by Regions
2.2.1 Lysosomal Storage Diseases Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Lysosomal Storage Diseases Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Lysosomal Storage Diseases Therapeutics Industry Dynamic
2.3.1 Lysosomal Storage Diseases Therapeutics Market Trends
2.3.2 Lysosomal Storage Diseases Therapeutics Market Drivers
2.3.3 Lysosomal Storage Diseases Therapeutics Market Challenges
2.3.4 Lysosomal Storage Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lysosomal Storage Diseases Therapeutics Players by Revenue
3.1.1 Global Top Lysosomal Storage Diseases Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Lysosomal Storage Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Lysosomal Storage Diseases Therapeutics Revenue
3.4 Global Lysosomal Storage Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Lysosomal Storage Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lysosomal Storage Diseases Therapeutics Revenue in 2020
3.5 Lysosomal Storage Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Lysosomal Storage Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Lysosomal Storage Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lysosomal Storage Diseases Therapeutics Breakdown Data by Type
4.1 Global Lysosomal Storage Diseases Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Type (2022-2027)
5 Lysosomal Storage Diseases Therapeutics Breakdown Data by Application
5.1 Global Lysosomal Storage Diseases Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Lysosomal Storage Diseases Therapeutics Market Size (2016-2027)
6.2 North America Lysosomal Storage Diseases Therapeutics Market Size by Type
6.2.1 North America Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2027)
6.3 North America Lysosomal Storage Diseases Therapeutics Market Size by Application
6.3.1 North America Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2027)
6.4 North America Lysosomal Storage Diseases Therapeutics Market Size by Country
6.4.1 North America Lysosomal Storage Diseases Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Lysosomal Storage Diseases Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Lysosomal Storage Diseases Therapeutics Market Size (2016-2027)
7.2 Europe Lysosomal Storage Diseases Therapeutics Market Size by Type
7.2.1 Europe Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2027)
7.3 Europe Lysosomal Storage Diseases Therapeutics Market Size by Application
7.3.1 Europe Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2027)
7.4 Europe Lysosomal Storage Diseases Therapeutics Market Size by Country
7.4.1 Europe Lysosomal Storage Diseases Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Lysosomal Storage Diseases Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Type
8.2.1 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Application
8.3.1 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Region
8.4.1 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Lysosomal Storage Diseases Therapeutics Market Size (2016-2027)
9.2 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Type
9.2.1 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Application
9.3.1 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Country
9.4.1 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Lysosomal Storage Diseases Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Type
10.2.1 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Application
10.3.1 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Country
10.4.1 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Details
11.1.2 Takeda Business Overview
11.1.3 Takeda Lysosomal Storage Diseases Therapeutics Introduction
11.1.4 Takeda Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
11.1.5 Takeda Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Lysosomal Storage Diseases Therapeutics Introduction
11.2.4 Pfizer Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Lysosomal Storage Diseases Therapeutics Introduction
11.3.4 Sanofi Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
11.3.5 Sanofi Recent Development
11.4 BioMarin Pharmaceutical
11.4.1 BioMarin Pharmaceutical Company Details
11.4.2 BioMarin Pharmaceutical Business Overview
11.4.3 BioMarin Pharmaceutical Lysosomal Storage Diseases Therapeutics Introduction
11.4.4 BioMarin Pharmaceutical Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
11.4.5 BioMarin Pharmaceutical Recent Development
11.5 Actelion Ltd
11.5.1 Actelion Ltd Company Details
11.5.2 Actelion Ltd Business Overview
11.5.3 Actelion Ltd Lysosomal Storage Diseases Therapeutics Introduction
11.5.4 Actelion Ltd Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
11.5.5 Actelion Ltd Recent Development
11.6 Raptor Pharmaceutical
11.6.1 Raptor Pharmaceutical Company Details
11.6.2 Raptor Pharmaceutical Business Overview
11.6.3 Raptor Pharmaceutical Lysosomal Storage Diseases Therapeutics Introduction
11.6.4 Raptor Pharmaceutical Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
11.6.5 Raptor Pharmaceutical Recent Development
11.7 Protalix Biotherapeutics
11.7.1 Protalix Biotherapeutics Company Details
11.7.2 Protalix Biotherapeutics Business Overview
11.7.3 Protalix Biotherapeutics Lysosomal Storage Diseases Therapeutics Introduction
11.7.4 Protalix Biotherapeutics Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
11.7.5 Protalix Biotherapeutics Recent Development
11.8 Amicus Therapeutics
11.8.1 Amicus Therapeutics Company Details
11.8.2 Amicus Therapeutics Business Overview
11.8.3 Amicus Therapeutics Lysosomal Storage Diseases Therapeutics Introduction
11.8.4 Amicus Therapeutics Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
11.8.5 Amicus Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Lysosomal Storage Diseases Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Enzyme Replacement Therapy
Table 3. Key Players of Stem Cell Therapy
Table 4. Key Players of Substrate Reduction Therapy
Table 5. Key Players of Other
Table 6. Global Lysosomal Storage Diseases Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Lysosomal Storage Diseases Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Lysosomal Storage Diseases Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Lysosomal Storage Diseases Therapeutics Market Share by Regions (2016-2021)
Table 10. Global Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Lysosomal Storage Diseases Therapeutics Market Share by Regions (2022-2027)
Table 12. Lysosomal Storage Diseases Therapeutics Market Trends
Table 13. Lysosomal Storage Diseases Therapeutics Market Drivers
Table 14. Lysosomal Storage Diseases Therapeutics Market Challenges
Table 15. Lysosomal Storage Diseases Therapeutics Market Restraints
Table 16. Global Lysosomal Storage Diseases Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Lysosomal Storage Diseases Therapeutics Market Share by Players (2016-2021)
Table 18. Global Top Lysosomal Storage Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Storage Diseases Therapeutics as of 2020)
Table 19. Ranking of Global Top Lysosomal Storage Diseases Therapeutics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Lysosomal Storage Diseases Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Lysosomal Storage Diseases Therapeutics Product Solution and Service
Table 23. Date of Enter into Lysosomal Storage Diseases Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Type (2016-2021)
Table 27. Global Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Lysosomal Storage Diseases Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Application (2016-2021)
Table 31. Global Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Lysosomal Storage Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Lysosomal Storage Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Lysosomal Storage Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Lysosomal Storage Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Lysosomal Storage Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Lysosomal Storage Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 63. Takeda Company Details
Table 64. Takeda Business Overview
Table 65. Takeda Lysosomal Storage Diseases Therapeutics Product
Table 66. Takeda Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 67. Takeda Recent Development
Table 68. Pfizer Company Details
Table 69. Pfizer Business Overview
Table 70. Pfizer Lysosomal Storage Diseases Therapeutics Product
Table 71. Pfizer Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 72. Pfizer Recent Development
Table 73. Sanofi Company Details
Table 74. Sanofi Business Overview
Table 75. Sanofi Lysosomal Storage Diseases Therapeutics Product
Table 76. Sanofi Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 77. Sanofi Recent Development
Table 78. BioMarin Pharmaceutical Company Details
Table 79. BioMarin Pharmaceutical Business Overview
Table 80. BioMarin Pharmaceutical Lysosomal Storage Diseases Therapeutics Product
Table 81. BioMarin Pharmaceutical Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 82. BioMarin Pharmaceutical Recent Development
Table 83. Actelion Ltd Company Details
Table 84. Actelion Ltd Business Overview
Table 85. Actelion Ltd Lysosomal Storage Diseases Therapeutics Product
Table 86. Actelion Ltd Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 87. Actelion Ltd Recent Development
Table 88. Raptor Pharmaceutical Company Details
Table 89. Raptor Pharmaceutical Business Overview
Table 90. Raptor Pharmaceutical Lysosomal Storage Diseases Therapeutics Product
Table 91. Raptor Pharmaceutical Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 92. Raptor Pharmaceutical Recent Development
Table 93. Protalix Biotherapeutics Company Details
Table 94. Protalix Biotherapeutics Business Overview
Table 95. Protalix Biotherapeutics Lysosomal Storage Diseases Therapeutics Product
Table 96. Protalix Biotherapeutics Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 97. Protalix Biotherapeutics Recent Development
Table 98. Amicus Therapeutics Company Details
Table 99. Amicus Therapeutics Business Overview
Table 100. Amicus Therapeutics Revenue in Lysosomal Storage Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 101. Amicus Therapeutics Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Lysosomal Storage Diseases Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Enzyme Replacement Therapy Features
Figure 3. Stem Cell Therapy Features
Figure 4. Substrate Reduction Therapy Features
Figure 5. Other Features
Figure 6. Global Lysosomal Storage Diseases Therapeutics Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Other Case Studies
Figure 10. Lysosomal Storage Diseases Therapeutics Report Years Considered
Figure 11. Global Lysosomal Storage Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Lysosomal Storage Diseases Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Lysosomal Storage Diseases Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Lysosomal Storage Diseases Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Lysosomal Storage Diseases Therapeutics Market Share by Players in 2020
Figure 16. Global Top Lysosomal Storage Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Storage Diseases Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Lysosomal Storage Diseases Therapeutics Revenue in 2020
Figure 18. Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Lysosomal Storage Diseases Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Lysosomal Storage Diseases Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Lysosomal Storage Diseases Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Lysosomal Storage Diseases Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Lysosomal Storage Diseases Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Lysosomal Storage Diseases Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Lysosomal Storage Diseases Therapeutics Market Share by Region (2016-2027)
Figure 40. China Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Lysosomal Storage Diseases Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Lysosomal Storage Diseases Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Lysosomal Storage Diseases Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Takeda Revenue Growth Rate in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
Figure 61. Sanofi Revenue Growth Rate in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
Figure 62. BioMarin Pharmaceutical Revenue Growth Rate in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
Figure 63. Actelion Ltd Revenue Growth Rate in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
Figure 64. Raptor Pharmaceutical Revenue Growth Rate in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
Figure 65. Protalix Biotherapeutics Revenue Growth Rate in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
Figure 66. Amicus Therapeutics Revenue Growth Rate in Lysosomal Storage Diseases Therapeutics Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
世界のリソソーム蓄積症市場規模・現状・予測（2021年-2027年） Lysosomal storage diseases (LSDs) refer to a group of diseases arising because of the deficiency of lysosomal enzymes, which leads to the accumulation of partially digested or undigested macromolecules inside the cell. According to the report, one driver in the market is unmet medical needs. Market …- 世界のリソソーム蓄積症（LSD）市場規模・現状・予測（2021年-2027年） Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Dis…
- 世界の多発性硬化症幹細胞治療市場規模・現状・予測（2021年-2027年） Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…
- 世界の多発性硬化症幹細胞治療市場規模・現状・予測（2021年-2027年） Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…
- 世界の犬幹細胞療法市場規模・現状・予測（2021年-2027年） The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic s…